NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study
Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting recent study results. According to the announcement, the successful in-vivo preclinical results are from SCNI’s innovative anti IL-17A/F VHH antibody fragment (“NanoAb”), which is being studied as a local, first-of-its-kind, intralesional biological treatment for from mild to moderate plaque psoriasis. An estimated million patients are diagnosed with plaque psoriasis in the United States, Japan and Europe. Scinai’s product candidate is designed to address the major shortcomings of currently available treatments. Testing confirmed the unique ability of Scinai’s NanoAb to neutralize both IL-17A and IL-17F isoforms and supported the concept that intralesional injection of a NanoAb blocking the IL-17 cytokine can impact the inflammatory cytokine cascade, leading to reduction in psoriatic lesion severity and improvement of the skin’s integrity. Based on the study results, Scinai plans to further refine dosing and drug half-life and then undergo a longer-duration, follow on in-vivo animal study later this year. “These positive results are very encouraging and mark a significant step forward in the development of a novel treatment for the underserved needs of the mild to moderate plaque psoriatic patients,” said Scinai Immunotherapeutics chief scientist Dr. Tamar Ben-Yedidia in the press release. “To date, most of the innovation related to treatment of autoimmune diseases has focused on drugs aimed at the more severe cases of these diseases, leaving milder cases mostly with generic topical drugs and phototherapy treatments. The mild psoriatic patients account for more than 50% of the plaque psoriatic patients and, while undertreated, they are prone to painful skin lesions sometimes in locations that generate a considerable disease burden for them. Scinai’s vision is to provide a highly efficacious, specific, convenient and safe local biologic treatment of plaque psoriasis lesions.”
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting recent study results. According to the announcement, the successful in-vivo preclinical results are from SCNI’s innovative anti IL-17A/F VHH antibody fragment (“NanoAb”), which is being studied as a local, first-of-its-kind, intralesional biological treatment for from mild to moderate plaque psoriasis. An estimated million patients are diagnosed with plaque psoriasis in the United States, Japan and Europe. Scinai’s product candidate is designed to address the major shortcomings of currently available treatments. Testing confirmed the unique ability of Scinai’s NanoAb to neutralize both IL-17A and IL-17F isoforms and supported the concept that intralesional injection of a NanoAb blocking the IL-17 cytokine can impact the inflammatory cytokine cascade, leading to reduction in psoriatic lesion severity and improvement of the skin’s integrity. Based on the study results, Scinai plans to further refine dosing and drug half-life and then undergo a longer-duration, follow on in-vivo animal study later this year. “These positive results are very encouraging and mark a significant step forward in the development of a novel treatment for the underserved needs of the mild to moderate plaque psoriatic patients,” said Scinai Immunotherapeutics chief scientist Dr. Tamar Ben-Yedidia in the press release. “To date, most of the innovation related to treatment of autoimmune diseases has focused on drugs aimed at the more severe cases of these diseases, leaving milder cases mostly with generic topical drugs and phototherapy treatments. The mild psoriatic patients account for more than 50% of the plaque psoriatic patients and, while undertreated, they are prone to painful skin lesions sometimes in locations that generate a considerable disease burden for them. Scinai’s vision is to provide a highly efficacious, specific, convenient and safe local biologic treatment of plaque psoriasis lesions.”
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
